A bispecific antibody is a drug that has been designed to simultaneously target two different antigens. Both targets may be expressed by a cancer cell, or these drugs may target both cancer cells and T cells. This approach gives additional options in targeted immunotherapy and may help the immune system find and kill the cancer cells.
GBR 1342 is a humanized, bispecific monoclonal antibody (bsAb) that is designed to activate the patient's immune system by redirecting immune cells towards tumor tissue, which may lead to targeted destruction of tumors.
BFCR4350A is a bispecific T-cell engager (BiTE) antibody. It targets both the the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and as well as the CD3 antigen found on T lymphocytes.
JNJ-64007957 is a bispecific antibody that targets BCMA, which is expressed in mature B lymphocytes, and CD3, which is expressed on T-cells.
AMG 701 is a bispecific antibody that targets both CD-3 and BCMA that is being tested in multiple myeloma.
AMG 420 is made using Amgen’s proprietary BiTE or “bispecific T-cell engager” technology. AMG 420 consists of two proteins fused together, each designed to interact with a specific target — in this case, BCMA and CD3, a protein found on the surface of T-cells.
AMG 424 is a novel, humanized, bispecific T cell-recruiting anti-CD3/CD38 antibody.
CC-93269 is a T-cell bi-specific antibody targeting both BCMA and CD3 in patients with multiple myeloma.
JNJ-64407564 is a bispecific monoclonal antibody binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells.
Create your account today and get matched to myeloma treatments and trials around the US.
Weekdays 9am - 5pm EST